Blood-based biomarkers and traumatic brain injury-A clinical perspective



: Posti Jussi P, Tenovuo Olli

Publisher: WILEY

: 2022

: Acta Neurologica Scandinavica

: ACTA NEUROLOGICA SCANDINAVICA

: ACTA NEUROL SCAND

: 11

: 0001-6314

DOI: https://doi.org/10.1111/ane.13620

: https://doi.org/10.1111/ane.13620


Blood-based biomarkers are promising tools to complement clinical variables and imaging findings in the diagnosis, monitoring and outcome prediction of traumatic brain injury (TBI). Several promising biomarker candidates have been found for various clinical questions, but the translation of TBI biomarkers into clinical applications has been negligible. Measured biomarker levels are influenced by patient-related variables such as age, blood-brain barrier integrity and renal and liver function. It is not yet fully understood how biomarkers enter the bloodstream from the interstitial fluid of the brain. In addition, the diagnostic performance of TBI biomarkers is affected by sampling timing and analytical methods. In this focused review, the clinical aspects of glial fibrillary acidic protein, neurofilament light, S100 calcium-binding protein B, tau and ubiquitin C-terminal hydrolase-L1 are examined. Current findings and clinical caveats are addressed.



Last updated on 2024-26-11 at 21:05